Our early research discovering immunogenic ERV-derived antigens
CSO Dr. Ray Jupp presented data on Ervaxx’s lead program at the 34th Society for Immunotherapy of Cancer (SITC) annual meeting in National Harbor, MD, USA on Saturday 9th November 2019.
The poster, entitled “Discovery of immunogenic ERV-derived antigens as targets for melanoma”, is the first publication of data generated with Ervaxx’ proprietary EDAPT™ platform, supporting the development of a therapeutic, off-the-shelf vaccine for melanoma.
